MedTrace Logo

Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy

NCT03480815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-06-09

No results posted yet for this study

Summary

This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe allergic asthma who are withdrawal of omalizumab therapy

Conditions

  • Severe Allergic Asthma

Interventions

DEVICE

Nocturnal Temperature Controlled Laminar Flow Device

Record of the time to first asthma exacerbation, lung function and exhaled NO level

OTHER

None Device

Record of the time to first asthma exacerbation, lung function and exhaled NO level

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chun-Hua Wang, MD · Department of Thoracic Medicine, Chang Gung Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2019-12-31
Completion
2020-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480815 on ClinicalTrials.gov